Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis.
Takayuki YoshinoJulien TaiebYasutoshi KubokiPer PfeifferAmit KumarHoward S HochsterPublished in: Therapeutic advances in medical oncology (2023)
Despite fewer patients treated with the combination, this meta-analysis consistently suggested that FTD/TPI + BEV provides benefits over FTD/TPI in refractory mCRC and has similar safety, except for more frequent grade ⩾3 neutropenia.